Results 271 to 280 of about 87,017 (286)

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Nature Reviews Cancer, 2019
Jonathan J Havel, Diego Chowell, Timothy A Chan   +2 more
exaly  

Appraising iniparib, the PARP inhibitor that never was—what must we learn?

Nature Reviews Clinical Oncology, 2013
Joaquin Mateo, Michael Ong, David S P Tan   +2 more
exaly  

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cell, 2020
Markus Hoffmann, Nadine Krüger, Tobias S Schiergens   +2 more
exaly  

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Nature Medicine, 2018
Yuting Sun, Jeffrey J Ackroyd, Stefan O Ciurea   +2 more
exaly  

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

Nature Reviews Cancer, 2008
Ludger Hengst, Joyce M Slingerland
exaly  

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

Nature, 2009
Michael A Milhollen, James J Garnsey, Lawrence R Dick   +2 more
exaly  

Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor

Nature Medicine, 2003
Laurent Meijer
exaly  

Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Nature Medicine, 2018
Jacqulyne Robichaux, Yasir Y Elamin, Zhi Tan   +2 more
exaly  

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

Cancer Cell, 2011
Wei Xu, Hui Yang, Ping Wang
exaly  

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Journal of Clinical Oncology, 2018
Christina Lacchetti, Michael B Atkins, Ian Chau   +2 more
exaly